TITLE

FDA Needs to Enhance Its Oversight of Drugs Approved on the Basis of Surrogate Endpoints

AUTHOR(S)
Crosse, Marcia
PUB. DATE
October 2009
SOURCE
GAO Reports;10/26/2009, preceding p1
SOURCE TYPE
Government Documents
DOC. TYPE
Article
ABSTRACT
The article focuses on a study by the U.S. Government Accountability Office (GAO) on approved drug applications based on surrogate endpoints under Food and Drug Administration's (FDA) accelerated and traditional approval process and the FDA's oversight of postmarketing studies. FDA is recommended by GAO to clarify conditions when it comes to expediting the withdrawal of drugs approved based on surrogate endpoints. GAO believes that this recommendation will enhance FDA's oversight.
ACCESSION #
45033208

 

Related Articles

  • Bioalliance Pharma files NDA for candidiasis drug.  // PharmaWatch: Biotechnology;Aug2009, Vol. 8 Issue 8, p12 

    The article reports on the new drug application of French biopharmaceutical company BioAlliance Pharma to the U.S. Food and Drug and Administration (FDA) in the U.S. BioAlliance has passed an drug application to FDA for the marketing approval of Loramyc, a mocuadhesive buccal tablets for the...

  • Recently Approved.  // Pharmaceutical Representative;Feb2009, Vol. 39 Issue 2, p12 

    The article offers information on the clinical drugs approved by the U.S. Food and Drugs Administration (FDA). Gleevec, Novartis AG's treatment of adult patients who underwent surgery for Kit (CD117)-positive gastrointestinal stromal tumors, has been authorized by FDA for new indication. FDA has...

  • Safety Requirements Slow Drug Approvals. Wechsler, Jill // Applied Clinical Trials;Nov2009, Vol. 18 Issue 11, p24 

    The article reports on the slow pace of drug approval by the Food and Drug Administration (FDA) in the U.S. It states that the approval of the FDA Amendments Act of 2007 poses new requirements for assessing postmarket studies and determine the need for Risk Evaluation and Mitigation Strategies...

  • FDA's Consideration of Evidence from Certain Clinical Trials. Crosse, Marcia // GAO Reports;8/30/2010, preceding p1 

    The article discusses a study conducted by the U.S. Government Accountability Office (GAO) on the Food and Drug Administration's (FDA's) decision for drug approval. The GAO examined the FDA's use of non-inferiority trial evidence to assess drug effectiveness by looking at new drug applications...

  • Accelerated Program Still Too Slow.  // Pharmaceutical Representative;Dec2009, Vol. 39 Issue 12, p11 

    The article presents a report released by the U.S. Government Accountability Office (GAO) on the U.S. Food and Drug Administration's (FDA) slow action plan and approval process of reviewing postmarket trials of drugs. The GAO examines 90 applications from 1992-2008 in which only 64 have been...

  • FDA Has Met Most Performance Goals for Reviewing Applications.  // GAO Reports;4/30/2012, preceding p1 

    The article offers information on a report prepared by the U.S. Government Accountability Office related to the performance goals achieved by the U.S. Food and Drug Administration (FDA) during the 2000-2010 fiscal year. It states that the FDA achieved its goal by the completion of the reviews...

  • GAO study of device approvals to take center stage at hearing. McCARTY, MARK // Medical Device Daily;4/14/2011, Vol. 15 Issue 72, p1 

    The article reports on a story featured on the online edition of the "New York Times" newspaper on April 12, 2011 which indicated that a report by the U.S. Government Accountability Office (GAO) will criticize the device approval process of the Food and Drug Administration (FDA). The question of...

  • Critical comparisons.  // Nature Medicine;Oct2010, Vol. 16 Issue 10, p1049 

    The author reflects on the U.S. Food and Drug Administration's (FDAs) use of noninferiority trials in investigating new drugs and its stance on the approval process for generic biologics. The author discusses the guidelines issued by the FDA in March 2010 on the use of noninferiority trials by...

  • GAO: FDA Is Unaware Of Own Budget Needs.  // Chain Drug Review;8/3/2009, Vol. 31 Issue 13, p50 

    The article reports on the statement made by the Government Accountability Office (GOA) that the U.S. Food and Drug Administration (FDA) lacks the means to predict its own budget requirements. GAO argues that FDA does not have the data to develop a complete and reliable estimate of the resources...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics